IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v14y2023i1d10.1038_s41467-023-39766-x.html
   My bibliography  Save this article

Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men

Author

Listed:
  • Suad Hannawi

    (Al Kuwait-Dubai (ALBaraha) Hospital)

  • Linda Saf Eldin

    (Al Kuwait-Dubai (ALBaraha) Hospital)

  • Alaa Abuquta

    (Al Kuwait-Dubai (ALBaraha) Hospital)

  • Ahmad Alamadi

    (Al Kuwait-Dubai (ALBaraha) Hospital)

  • Sally A. Mahmoud

    (G42 Healthcare)

  • Aala Hassan

    (Al Kuwait-Dubai (ALBaraha) Hospital)

  • Shuping Xu

    (Sinocelltech Ltd.)

  • Jian Li

    (Sinocelltech Ltd.)

  • Dongfang Liu

    (Sinocelltech Ltd.)

  • Adam Abdul Hakeem Baidoo

    (Sinocelltech Ltd.)

  • Dima Ibrahim

    (Burjeel Medical City)

  • Mojtaba Alhaj

    (Burjeel Medical City)

  • Yuanxin Chen

    (Sinocelltech Ltd.)

  • Qiang Zhou

    (Sinocelltech Ltd.)

  • Liangzhi Xie

    (Sinocelltech Ltd.
    Chinese Academy of Medical Sciences & Peking Union Medical College)

Abstract

The safety and immunogenicity of a protein-based tetravalent vaccine SCTV01E that contains spike protein ectodomain (S-ECD) of Alpha, Beta, Delta and Omicron BA.1 are assessed and compared with bivalent protein vaccine SCTV01C (Alpha and Beta variants) and monovalent mRNA vaccine (NCT05323461). The primary endpoints are the geometric mean titers (GMT) of live virus neutralizing antibodies (nAb) to Delta (B.1.617.2) and Omicron BA.1 at day 28 post-injection. The secondary endpoints include the safety, day 180 GMTs against Delta and Omicron BA.1, day 28 GMTs to BA.5, and seroresponse rates of neutralizing antibodies and T cell responses at day 28 post-injection. 450 participants, comprising of 449 males and 1 female, with a median age (range) of 27 (18–62) years, are assigned to receive one booster dose of BNT162b2, 20 µg SCTV01C or 30 µg SCTV01E and completed 4-week follow-up. All SCTV01E related adverse events (AEs) are mild or moderate and no Grade ≥3 AE, serious AE or new safety concerns are identified. Day 28 GMT of live virus neutralizing antibodies and seroresponse against Omicron BA.1 and BA.5 with SCTV01E are significantly higher than those with SCTV01C and BNT162b2. These data indicate an overall neutralization superiority with tetravalent booster immunization in men.

Suggested Citation

  • Suad Hannawi & Linda Saf Eldin & Alaa Abuquta & Ahmad Alamadi & Sally A. Mahmoud & Aala Hassan & Shuping Xu & Jian Li & Dongfang Liu & Adam Abdul Hakeem Baidoo & Dima Ibrahim & Mojtaba Alhaj & Yuanxin, 2023. "Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men," Nature Communications, Nature, vol. 14(1), pages 1-9, December.
  • Handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-39766-x
    DOI: 10.1038/s41467-023-39766-x
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-023-39766-x
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-023-39766-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Christian Gaebler & Zijun Wang & Julio C. C. Lorenzi & Frauke Muecksch & Shlomo Finkin & Minami Tokuyama & Alice Cho & Mila Jankovic & Dennis Schaefer-Babajew & Thiago Y. Oliveira & Melissa Cipolla & , 2021. "Evolution of antibody immunity to SARS-CoV-2," Nature, Nature, vol. 591(7851), pages 639-644, March.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Ruizhi Zhang & Junshi Zhao & Xiaoping Zhu & Qinghu Guan & Shujun Liu & Meihong Li & Jianghua Gao & Jie Tan & Feng Cao & Beifang Gan & Bo Wu & Jin Bai & Youquan Liu & Gang Xie & Chi Liu & Wei Zhao & Li, 2024. "Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trial," Nature Communications, Nature, vol. 15(1), pages 1-11, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Haisheng Yu & Banghui Liu & Yudi Zhang & Xijie Gao & Qian Wang & Haitao Xiang & Xiaofang Peng & Caixia Xie & Yaping Wang & Peiyu Hu & Jingrong Shi & Quan Shi & Pingqian Zheng & Chengqian Feng & Guofan, 2023. "Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    2. Ramon Roozendaal & Laura Solforosi & Daniel J. Stieh & Jan Serroyen & Roel Straetemans & Anna Dari & Muriel Boulton & Frank Wegmann & Sietske K. Rosendahl Huber & Joan E. M. van der Lubbe & Jenny Hend, 2021. "SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques," Nature Communications, Nature, vol. 12(1), pages 1-10, December.
    3. Leire Campos-Mata & Benjamin Trinité & Andrea Modrego & Sonia Tejedor Vaquero & Edwards Pradenas & Anna Pons-Grífols & Natalia Rodrigo Melero & Diego Carlero & Silvia Marfil & César Santiago & Dàlia R, 2024. "A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    4. Meriem Bekliz & Kenneth Adea & Pauline Vetter & Christiane S. Eberhardt & Krisztina Hosszu-Fellous & Diem-Lan Vu & Olha Puhach & Manel Essaidi-Laziosi & Sophie Waldvogel-Abramowski & Caroline Stephan , 2022. "Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    5. Lisa-Marie Funk & Gereon Poschmann & Fabian Rabe von Pappenheim & Ashwin Chari & Kim M. Stegmann & Antje Dickmanns & Marie Wensien & Nora Eulig & Elham Paknia & Gabi Heyne & Elke Penka & Arwen R. Pear, 2024. "Multiple redox switches of the SARS-CoV-2 main protease in vitro provide opportunities for drug design," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    6. Grace Kenny & Sophie O’Reilly & Neil Wrigley Kelly & Riya Negi & Colette Gaillard & Dana Alalwan & Gurvin Saini & Tamara Alrawahneh & Nathan Francois & Matthew Angeliadis & Alejandro Abner Garcia Leon, 2023. "Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time," Nature Communications, Nature, vol. 14(1), pages 1-11, December.
    7. Daniel M. Altmann & Catherine J. Reynolds & George Joy & Ashley D. Otter & Joseph M. Gibbons & Corinna Pade & Leo Swadling & Mala K. Maini & Tim Brooks & Amanda Semper & Áine McKnight & Mahdad Noursad, 2023. "Persistent symptoms after COVID-19 are not associated with differential SARS-CoV-2 antibody or T cell immunity," Nature Communications, Nature, vol. 14(1), pages 1-9, December.
    8. Brian Walitt & Komudi Singh & Samuel R. LaMunion & Mark Hallett & Steve Jacobson & Kong Chen & Yoshimi Enose-Akahata & Richard Apps & Jennifer J. Barb & Patrick Bedard & Robert J. Brychta & Ashura Wil, 2024. "Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome," Nature Communications, Nature, vol. 15(1), pages 1-29, December.
    9. Caitlin I. Stoddard & Kevin Sung & Zak A. Yaffe & Haidyn Weight & Guillaume Beaudoin-Bussières & Jared Galloway & Soren Gantt & Judith Adhiambo & Emily R. Begnel & Ednah Ojee & Jennifer Slyker & Dalto, 2023. "Elevated binding and functional antibody responses to SARS-CoV-2 in infants versus mothers," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    10. Héctor López-Mendoza & Antonio Montañés & F. Javier Moliner-Lahoz, 2021. "Disparities in the Evolution of the COVID-19 Pandemic between Spanish Provinces," IJERPH, MDPI, vol. 18(10), pages 1-20, May.
    11. Lei Peng & Yingxia Hu & Madeleine C. Mankowski & Ping Ren & Rita E. Chen & Jin Wei & Min Zhao & Tongqing Li & Therese Tripler & Lupeng Ye & Ryan D. Chow & Zhenhao Fang & Chunxiang Wu & Matthew B. Dong, 2022. "Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    12. Robert W. Aldridge & Alexei Yavlinsky & Vincent Nguyen & Max T. Eyre & Madhumita Shrotri & Annalan M. D. Navaratnam & Sarah Beale & Isobel Braithwaite & Thomas Byrne & Jana Kovar & Ellen Fragaszy & Wi, 2022. "SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort," Nature Communications, Nature, vol. 13(1), pages 1-8, December.
    13. Maja Socan & Katarina Prosenc & Maja Mrzel, 2023. "Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave," IJERPH, MDPI, vol. 20(4), pages 1-14, February.
    14. Lucie Bernard-Raichon & Mericien Venzon & Jon Klein & Jordan E. Axelrad & Chenzhen Zhang & Alexis P. Sullivan & Grant A. Hussey & Arnau Casanovas-Massana & Maria G. Noval & Ana M. Valero-Jimenez & Jua, 2022. "Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia," Nature Communications, Nature, vol. 13(1), pages 1-13, December.
    15. Xiang Liu & Wern Hann Ng & Eva Zusinaite & Joseph Freitas & Adam Taylor & Venugopal Yerragunta & Shukra Madhaha Aavula & Sambaiah Gorriparthi & Santhakumar Ponsekaran & Rama Lakshmi Bonda & Priyanka M, 2024. "A single-dose intranasal live-attenuated codon deoptimized vaccine provides broad protection against SARS-CoV-2 and its variants," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    16. Yubin Liu & Ziyi Wang & Xinyu Zhuang & Shengnan Zhang & Zhicheng Chen & Yan Zou & Jie Sheng & Tianpeng Li & Wanbo Tai & Jinfang Yu & Yanqun Wang & Zhaoyong Zhang & Yunfeng Chen & Liangqin Tong & Xi Yu, 2023. "Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    17. Marco Mandolesi & Hrishikesh Das & Liset Vries & Yiqiu Yang & Changil Kim & Manojj Dhinakaran & Xaquin Castro Dopico & Julian Fischbach & Sungyong Kim & Mariia V. Guryleva & Monika Àdori & Mark Cherny, 2024. "Multi-compartmental diversification of neutralizing antibody lineages dissected in SARS-CoV-2 spike-immunized macaques," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    18. André Santa Cruz & Ana Mendes-Frias & Marne Azarias-da-Silva & Sónia André & Ana Isabel Oliveira & Olga Pires & Marta Mendes & Bárbara Oliveira & Marta Braga & Joana Rita Lopes & Rui Domingues & Ricar, 2023. "Post-acute sequelae of COVID-19 is characterized by diminished peripheral CD8+β7 integrin+ T cells and anti-SARS-CoV-2 IgA response," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    19. Irene A. Abela & Chloé Pasin & Magdalena Schwarzmüller & Selina Epp & Michèle E. Sickmann & Merle M. Schanz & Peter Rusert & Jacqueline Weber & Stefan Schmutz & Annette Audigé & Liridona Maliqi & Anni, 2021. "Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity," Nature Communications, Nature, vol. 12(1), pages 1-18, December.
    20. Mark Chernyshev & Mrunal Sakharkar & Ruth I. Connor & Haley L. Dugan & Daniel J. Sheward & C. G. Rappazzo & Aron Stålmarck & Mattias N. E. Forsell & Peter F. Wright & Martin Corcoran & Ben Murrell & L, 2023. "Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages," Nature Communications, Nature, vol. 14(1), pages 1-12, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-39766-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.